Updated on 16 July 2014
In trials, the software has been shown to be almost twice as effective as traditional dosing methods
Singapore: In a bid to launch overseas and to expand its Australian operations, Brisbane-based personalised medicine start-up DoseMe has secured $500,000 in investment funding.
The company is said to be marketing a proprietary software technology designed to allow clinicians to prescribe medicines based on a patient's individual ability to absorb, process and clear a drug.
A report said that it uses simple information including a patient's height, weight and gender to generate complex treatment algorithms based on Bayesian dosing principles.
The software is also said to then incorporate patient-specific lab results and continues to learn and adjust doses over time.
Currently supporting 13 medications across four therapeutic areas, DoseMe software is available via mobile devices, a web-based application and as a module to integrate into patient management software. The therapeutic areas include anti-microbial, chemotherapy, anti-coagulants and pro-coagulants.